Is There A Common Neuronal Basis for Autism and Catatonia?

Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, Mississippi 39216, USA.
International Review of Neurobiology (Impact Factor: 1.92). 02/2006; 72:151-64. DOI: 10.1016/S0074-7742(05)72009-2
Source: PubMed


Neuronal bases for autism and catatonia are unknown although integrative theories may soon become feasible as research in autism and catatonia advances. Catatonia and autism may both qualify as neurobiological syndromes in their own right. There is emerging evidence that catatonia may be a common syndrome in autism. Although the relation between autism and catatonia is unclear, coexpression of autism and catatonia may be due to abnormalities in common neuronal circuitries. This possibility constitutes another level of complexity to neurobiological inquiry, but also provides an opportunity to advance our understanding of both disorders. There is a great potential benefit in studying the relation between catatonia and autism in order to focus future research on subtype-specific causes and treatments. Future research avenues are outlined.

Download full-text


Available from: Dirk Dhossche,
  • Source
    • "Despite assertions by several authors regarding the safety and efficacy of ECT in this population (Dhossche et al. 2010; Ghaziuddin et al. 2010; Wachtel et al. 2008; Fink et al. 2006), the evidence underlying these assertions is weak. The number of cases reported is small, and the quality of data is low, largely due to poor outcome measurement , incomplete description of treatments and failure to address confounding factors. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A systematic review was conducted to examine the efficacy of a range of treatments for autistic catatonia. The review identified 22 relevant papers, reporting a total of 28 cases including both adult and paediatric patients. Treatment methods included electroconvulsive therapy (ECT), medication, behavioural and sensory interventions. Quality assessment found the standard of the existing literature to be generally poor, with particular limitations in treatment description and outcome measurement. There is some limited evidence to support the use of ECT, high dose lorazepam and behavioural interventions for people with autistic catatonia. However, there is a need for controlled, high-quality trials. Reporting of side effects and adverse events should also be improved, in order to better evaluate the safety of these treatments.
    Journal of Autism and Developmental Disorders 03/2014; 44(9). DOI:10.1007/s10803-014-2085-y · 3.06 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A brief overview is given of the properties of the spherical multipole model. Attention is paid to two approaches for the estimation of the multipole moments, namely a method using numerical integration and a method using linear regression. The advantages and disadvantages of both methods are highlighted. The authors also describe the methods and results of a statistical study proving at a significance level of p=0.05 the presence of supplementary diagnostic information in higher-degree multipole moments when these are added to the dipole moments (the VCG). The authors also examine the problem of representing detailed surface potential signal information using a spherical multipole model.
    Engineering in Medicine and Biology Society, 1988. Proceedings of the Annual International Conference of the IEEE; 12/1988
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Catatonia is a common neuropsychiatric syndrome which may arise from GABA-A hypoactivity, dopamine (D2) hypoactivity,and possibly glutamate NMDA hyperactivity. Amantadine and memantine have been reported as effective treatments for catatonia in selected cases, and probably mediate the presence of catatonic signs and symptoms through complex pathways involving glutamate antagonism. The authors identified 25 cases of catatonia treated with either agent. This article provides indirect evidence that glutamate antagonists may improve catatonic signs in some patients who fail to respond to established treatment, including lorazepam or electroconvulsive therapy. Further study of glutamate antagonists in the treatment of catatonia is needed.
    Journal of Neuropsychiatry 02/2007; 19(4):406-12. DOI:10.1176/appi.neuropsych.19.4.406 · 2.82 Impact Factor
Show more